SCYNEXIS Inc (NASDAQ:SCYX) insider Gonzalez David Angulo acquired 14,790 shares of the company’s stock in a transaction that occurred on Thursday, March 8th. The stock was purchased at an average cost of $1.69 per share, with a total value of $24,995.10. Following the acquisition, the insider now directly owns 88,790 shares of the company’s stock, valued at approximately $150,055.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of SCYNEXIS Inc (NASDAQ SCYX) opened at $1.46 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.30 and a current ratio of 7.30. SCYNEXIS Inc has a 1-year low of $1.35 and a 1-year high of $3.24.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of SCYNEXIS by 6.0% in the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock valued at $1,554,000 after purchasing an additional 48,978 shares during the period. GSA Capital Partners LLP grew its holdings in shares of SCYNEXIS by 17.1% in the third quarter. GSA Capital Partners LLP now owns 206,900 shares of the company’s stock valued at $499,000 after purchasing an additional 30,200 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of SCYNEXIS in the third quarter valued at about $264,000. 30.95% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Insider Buying: SCYNEXIS Inc (SCYX) Insider Purchases 14,790 Shares of Stock” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://stocknewstimes.com/2018/03/13/insider-buying-scynexis-inc-scyx-insider-purchases-14790-shares-of-stock.html.
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.